The effect of resveratrol on hypertension: A clinical trial

Theodotou,Marios; Fokianos,Konstantinos; Mouzouridou,Alexia; Konstantinou,Cornelia; Aristotelous,Andrea; Prodromou,Dafni; Chrysikou,Asimina

doi:10.3892/etm.2016.3958

The effect of resveratrol on hypertension: A clinical trial

Authors:
- Marios Theodotou
- Konstantinos Fokianos
- Alexia Mouzouridou
- Cornelia Konstantinou
- Andrea Aristotelous
- Dafni Prodromou
- Asimina Chrysikou
View Affiliations

Affiliations: Riegler, Ltd., Institute of Medical Clinical Trials, Limassol 3020, Cyprus, Department of Mathematics and Statistics, University of Cyprus, Nicosia 20537, Cyprus, Agios Efrem, Advanced Medical Diagnostic Center, Limassol 3020, Cyprus
Published online on: December 6, 2016 https://doi.org/10.3892/etm.2016.3958
Pages: 295-301
Copyright: © Theodotou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this clinical trial was to investigate the effects of Evelor, a micronized formulation of resveratrol (RESV; 3,5,4'-trihydroxy-trans-stilbene), in patients with primary hypertension. RESV is a stilbenoid and phytoalexin produced by several plants in response to injury or attack by pathogens, such as bacteria and fungi. Patients included in the clinical trial were split into the following two groups, based on the severity of their disease: Group A (n=46), stage I hypertension [systolic blood pressure (SBP), 140‑159 mmHg; diastolic blood pressure (DBP), 90‑99 mmHg] and Group B (n=51), stage II hypertension (SBP, 160‑179 mmHg; DBP, 100‑109 mmHg). Each group was divided into two subgroups: A1 and B1, patients treated with standard antihypertensive therapy (A1, 10 mg Dapril; B1, 20 mg Dapril), and A2 and B2, patients treated with antihypertensive therapy (Dapril) plus Evelor. The present study aimed to determine the effects of Evelor, in addition to the standard hypertension treatment, and its effect on the hepatic enzymes serum glutamate-pyruvate transaminase (SGPT) and gamma‑glutamyl transferase (gamma‑GT). Following the trial, which lasted two years (October 2010 to October 2012), the mean blood pressure of both groups lay within the normal range, indicating that blood pressure was efficiently controlled. The results of the present study demonstrate that the addition of RESV to standard antihypertensive therapy is sufficient to reduce blood pressure to normal levels, without the need for additional antihypertensive drugs. In addition, statistical analysis of the results identified a significant reduction in plasma concentration levels of SGPT (P<0.001) and gamma‑GT (P<0.001) with the addition of RESV, indicating that RESV prevents liver damage.

View Figures

View References

1	Kannel WB: Fifty years of framingham study contributions to understanding hypertension. J Hum Hypertens. 14:83–90. 2000. View Article : Google Scholar : PubMed/NCBI
2	Baena CP, Olandoski M, Younge JO, Buitrago-Lopez A, Darweesh SK, Campos N, Sedaghat S, Sajjad A, van Herpt TT, Freak-Poli R, et al: Effects of lifestyle-related interventions on blood pressure in low and middle-income countries: Systematic review and meta-analysis. J Hypertens. 32:961–973. 2014. View Article : Google Scholar : PubMed/NCBI
3	Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, Williams B and Ford GA: Lifestyle interventions to reduce raised blood pressure: A systematic review of randomized controlled trials. J Hypertens. 24:215–233. 2006. View Article : Google Scholar : PubMed/NCBI
4	Lifton RP, Gharavi AG and Geller DS: Molecular mechanisms of human hypertension. Cell. 104:545–556. 2001. View Article : Google Scholar : PubMed/NCBI
5	Timberlake DS, O'Connor DT and Parmer RJ: Molecular genetics of essential hypertension: Recent results and emerging strategies. Curr Opin Nephrol Hypertens. 10:71–79. 2001. View Article : Google Scholar : PubMed/NCBI
6	Singh M, Mensah GA and Bakris G: Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 28:545–559. 2010. View Article : Google Scholar : PubMed/NCBI
7	Szmitko PE and Verma S: Cardiology patient pages. Red wine and your heart. Circulation. 111:e10–e11. 2005. View Article : Google Scholar : PubMed/NCBI
8	Duffy SJ and Vita JA: Effects of phenolics on vascular endothelial function. Curr Opin Lipidol. 14:21–27. 2003. View Article : Google Scholar : PubMed/NCBI
9	Ferrières J: The French paradox: Lessons for other countries. Heart. 90:107–111. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kopp P: Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the ‘French paradox’? Eur J Endocrinol. 138:619–620. 1998. View Article : Google Scholar : PubMed/NCBI
11	Fremont L: Biological effects of resveratrol. Life Sci. 66:663–673. 2000. View Article : Google Scholar : PubMed/NCBI
12	EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), . Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97. EFSA J. 14:43682016. View Article : Google Scholar
13	Dolinsky VW, Chan AY, Frayne I Robillard, Light PE, Des Rosiers C and Dyck JR: Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation. 119:1643–1652. 2009. View Article : Google Scholar : PubMed/NCBI
14	Cao X, Luo T, Luo X and Tang Z: Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertens Res. 37:803–810. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK and He J: Global burden of hypertension: Analysis of worldwide data. Lancet. 365:217–223. 2005. View Article : Google Scholar : PubMed/NCBI
16	World Health Organization. A global brief on hypertension, . Silent killer, global public health crises (World Health Day 2013). Geneva: WHO;
17	The World health statistics 2012 report. Geneva: WHO;
18	Kearney PM, Whelton M, Reynolds K, Whelton PK and He J: Worldwide prevalence of hypertension: A systematic review. J Hypertens. 22:11–19. 2004. View Article : Google Scholar : PubMed/NCBI
19	Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B and Thamm M: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 43:10–17. 2004. View Article : Google Scholar : PubMed/NCBI
20	Kuneš J, Kadlecová M, Vaněčková I and Zicha J: Critical developmental periods in the pathogenesis of hypertension. Physiol Res. 61:(Suppl 1). S9–S17. 2012.PubMed/NCBI
21	Kunes J and Zicha J: The interaction of genetic and environmental factors in the etiology of hypertension. Physiol Res. 58:(Suppl 2). S33–S41. 2009.PubMed/NCBI
22	Widlansky ME, Gokce N, Keaney JF Jr and Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 42:1149–1160. 2003. View Article : Google Scholar : PubMed/NCBI
23	Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G and Nishigaki I: The vascular endothelium and human diseases. Int J Biol Sci. 9:1057–1069. 2013. View Article : Google Scholar : PubMed/NCBI
24	Klatz R and Goldman R: A4M American academy of anti-aging medicine. Anti-Aging Therapeutics. XVI:Chapter 11. 2015.
25	Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N and Stefanadis C: The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 10:4–18. 2012. View Article : Google Scholar : PubMed/NCBI
26	Furchgott RF and Zawadzki J: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:373–376. 1980. View Article : Google Scholar : PubMed/NCBI
27	Ignarro LJ, Byrns RE and Wood KS: Biochemical and pharmacological properties of endothelium-derived relaxing factor and its similarity to nitric oxide radicalVasodilatation: Vascular smooth muscle peptides, autonomic nerves and endothelium. Vanhoutte P.M.: Raven Press; New York: pp. 427–436. 1988
28	Furchgott RF and Vanhoutte PM: Endothelium-derived relaxing and contracting factors. FASEB J. 3:2007–2018. 1989.PubMed/NCBI
29	SoRelle R: Nobel prize awarded to scientists for nitric oxide discoveries. Circulation. 98:2365–2366. 1998. View Article : Google Scholar : PubMed/NCBI
30	Hermann M, Flammer A and Lüscher TF: Nitric oxide in hypertension. J Clin Hypertens (Greenwich). 8:(12 Suppl 4). S17–S29. 2006. View Article : Google Scholar
31	Endemann DH and Schiffrin EL: Endothelial dysfunction. J Am Soc Nephrol. 15:1983–1992. 2004. View Article : Google Scholar : PubMed/NCBI
32	de la Sierra A and Larrousse M: Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens. 24:373–379. 2010. View Article : Google Scholar : PubMed/NCBI
33	Dolinsky VW, Morton JS, Oka T, Robillard-Frayne I, Bagdan M, Lopaschuk GD, Des Rosiers C, Walsh K, Davidge ST and Dyck JR: Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension. 56:412–421. 2010. View Article : Google Scholar : PubMed/NCBI
34	Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS, Nagendran J, Lopaschuk GD, et al: Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta. 1832:1723–1733. 2013. View Article : Google Scholar : PubMed/NCBI
35	Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, de Montellano PR Ortiz and Kemp BE: AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 443:285–289. 1999. View Article : Google Scholar : PubMed/NCBI
36	Zhang J, Xie Z, Dong Y, Wang S, Liu C and Zou MH: Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem. 283:27452–27461. 2008. View Article : Google Scholar : PubMed/NCBI